Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neoplasm Metastasis × enzalutamide × Clear all

Phase

Phase 2 7 Phase 1 4 Phase 3 3 Phase NA 1 Phase 4 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 2 Neoplasm Metastasis 1 Castration-resistant Prostate Cancer Patients with Oligometastases 1

Interventions

Gemcitabine 5 Capecitabine 4 pembrolizumab 3 Fluorouracil 3 Cisplatin 3 vinflunine 2 cabazitaxel 2 Ipilimumab 2 Haloperidol 2 trifluridine tipiracil drug combination 1 racemetyrosine 1 nimotuzumab 1 futibatinib 1 exemestane 1 enzalutamide 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 beta-Glucans 1 auricularum 1 atezolizumab 1 apatinib 1 abiraterone 1 XELOX 1 Water 1 Waiting Lists 1 Taxes 1 Tamoxifen 1 Sunitinib 1 Starch 1 Sirolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03295565 2022-04-15

OSTRICh

The Netherlands Cancer Institute

Phase 2/3 Completed

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡